Genzyme: “Must keep Boston R&D intact”

Posted on 20. Jan, 2011 by in News

According to a recent Boston Globe article, Genzyme CEO Henri Termeer stated:

“That any purchaser Genyzme would want to keep its Boston area research and manufacturing operations intact, noting that the company’s science and its people are a key source of biotechnology innovation.  “Only then will they get the return on their investment,” he said.”

“With a takeover offer from French drug maker Sanofi-Aventis SA set to expire Friday at midnight, Termeer  told Boston business leaders, “It will take time” to negotiate an acquisition of the state’s largest biotechnology company.”

It will be interesting to see how Genzyme handles the unsolicited offer and how Sanofi or another buyer handles Genzyme’s  research and manufacturing operations in Cambridge.

Tags: , ,

No comments.

Leave a Reply